LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• LivaNova PLC (NASDAQ:LIVN) has received a consensus recommendation of "Moderate Buy" from seven research firms, with one hold rating and six buy ratings.
• The average 12-month target price for LivaNova's stock is $59.71, with notable price targets set at $64.00 by Needham and $58.00 by Barclays.
• LivaNova reported $1.05 earnings per share for the last quarter, exceeding expectations and marking a 10.6% revenue increase year-over-year.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $59.7143.

LIVN has been the topic of a number of analyst reports. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Wednesday, September 3rd. Barclays raised their price target on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently bought and sold shares of LIVN. GAMMA Investing LLC increased its position in shares of LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company's stock worth $28,000 after purchasing an additional 407 shares in the last quarter. State of Wyoming acquired a new stake in shares of LivaNova during the second quarter worth about $31,000. EverSource Wealth Advisors LLC increased its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company's stock worth $32,000 after purchasing an additional 639 shares in the last quarter. UMB Bank n.a. increased its position in shares of LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after purchasing an additional 647 shares in the last quarter. Finally, CWM LLC increased its position in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after purchasing an additional 299 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Up 2.2%

NASDAQ:LIVN opened at $53.44 on Monday. The firm has a market cap of $2.92 billion, a PE ratio of -13.74 and a beta of 0.96. The stock has a fifty day moving average price of $51.80 and a 200 day moving average price of $45.10. LivaNova has a 12-month low of $32.48 and a 12-month high of $58.91. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. During the same period last year, the business posted $0.93 earnings per share. LivaNova's revenue was up 10.6% compared to the same quarter last year. Sell-side analysts anticipate that LivaNova will post 2.85 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.